Profound Medical (TSE:PRN) Shares Down 0.2% – Should You Sell?

Profound Medical Corp. (TSE:PRN) was down 0.2% during trading on Tuesday . The stock traded as low as C$10.30 and last traded at C$10.30. Approximately 9,329 shares were traded during trading, an increase of 33% from the average daily volume of 7,004 shares. The stock had previously closed at C$10.32.

Profound Medical Stock Down 0.3 %

The firm has a 50 day moving average of C$11.22 and a 200 day moving average of C$11.56. The firm has a market cap of C$244.31 million, a price-to-earnings ratio of -6.03 and a beta of 0.81. The company has a quick ratio of 14.98, a current ratio of 8.61 and a debt-to-equity ratio of 16.95.

Profound Medical (TSE:PRN) last announced its quarterly earnings results on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.38). The firm had revenue of C$3.06 million during the quarter, compared to the consensus estimate of C$3.42 million. As a group, sell-side analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insider Activity

In other Profound Medical news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. Corporate insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.